We also evaluated other prognosis-related factors and found that MYC was more commonly expressed in CD5+ DLBCL (17/24, P < 0.05), while we did not find a significant difference in BCL-2 and BCL-6 expression between CD5+ and CD5- DLBCL (P > 0.05). The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.